49 citations
,
December 2022 in “Pharmacological Reviews” Targeting androgen receptors shows promise for treating triple-negative breast cancer, but more research is needed.
2 citations
,
February 2023 in “Actas Dermo-Sifiliográficas” Baricitinib effectively improved both atopic dermatitis and alopecia areata symptoms in a patient.
October 2024 in “American Journal of Case Reports” Baricitinib improved hair loss and arthritis in a lupus patient.
November 2023 in “SKIN The Journal of Cutaneous Medicine” December 2013 in “Cumhuriyet Tıp Dergisi/Cumhuriyet Üniversitesi Tıp Fakültesi dergisi” Erlotinib can cause acne-like skin issues, needing early treatment and possible dosage adjustments.
September 2024 in “Journal of the American Academy of Dermatology” Baricitinib helps long-term hair regrowth in severe alopecia areata patients.
The treatment was not recommended due to limited effectiveness and significant side effects.
Baricitinib may reactivate trichilemmal cysts in people with a history of these cysts.
January 2024 in “Revista de la Asociación Colombiana de Dermatología y Cirugía Dermatológica/Revista de la Asociacion Colombiana de Dermatologia y Cirugia Dermatologica” Baricitinib successfully treated severe hair loss.
January 2026 in “Clinical and Experimental Dermatology” Ruxolitinib helped a patient with alopecia areata regrow hair.
Upadacitinib effectively treated a patient with multiple inflammatory conditions.
January 2026 in “Dermatology Reports” Upadacitinib improved symptoms and hair regrowth in a teen with multiple autoimmune conditions.
1 citations
,
February 2025 in “International Journal of Dermatology” Abrocitinib may effectively treat Lichen Planopilaris.
Baricitinib is effective for Alopecia Areata but requires careful patient history evaluation.
14 citations
,
April 2023 in “Acta Dermato Venereologica” Upadacitinib effectively treated severe hair loss in a child.
JAK inhibitors effectively regrow hair in alopecia areata but hair loss often returns after stopping treatment.
February 2024 in “Frontiers in Cell and Developmental Biology” Eribulin-based chemotherapy is more effective and has fewer side effects for advanced triple-negative breast cancer.
March 2026 in “SHILAP Revista de lepidopterología” Rituximab may cause skin issues, but baricitinib can help improve them.
September 2024 in “Journal of the American Academy of Dermatology” Baricitinib maintains significant hair regrowth in severe alopecia areata over three years.
October 2023 in “Regular and Young Investigator Award Abstracts” Baricitinib treatment helped reduce hair loss symptoms in mice by decreasing inflammation-related immune cells.
Olumiant® (Baricitinib) is effective for treating hair loss from Alopecia Areata.
October 2024 in “BMJ Case Reports” Baricitinib effectively treats both rheumatoid arthritis and alopecia areata.
BMD-1141 effectively regrows hair in alopecia areata with less frequent dosing than current treatments.
12 citations
,
July 2023 in “Journal of the European Academy of Dermatology and Venereology” Upadacitinib improved Crohn's disease, atopic dermatitis, and alopecia areata in one patient.
1 citations
,
June 2023 in “American Journal of Clinical Dermatology” Baricitinib helps regrow hair in severe alopecia areata but has side effects like infections and headaches.
September 2025 in “International Journal of Molecular Sciences” Deucravacitinib may help treat various immune diseases beyond psoriasis, but more research is needed.
2 citations
,
May 2017 in “Journal of the American Academy of Dermatology” Tofacitinib helped a 19-year-old regrow hair after other treatments failed.
The combination of high-dose toremifene and capecitabine was effective for advanced recurrent breast cancer.
April 2023 in “Journal of Investigative Dermatology” ALRN-6924 can protect hair follicles from chemotherapy damage by temporarily stopping cell division.
10 citations
,
January 2023 in “SAGE Open Medical Case Reports” Upadacitinib may effectively treat both alopecia universalis and Crohn's disease.